60 Degrees Pharma to Disclose Tafenoquine Babesiosis Trial Results on October 6
On October 1, 2026, 60 Degrees Pharmaceuticals announced it will disclose interim clinical trial results for tafenoquine in hospitalized severe babesiosis patients on October 6, 2026. The company previously crossed ... Read More